Twist Bioscience Corporation (TWST) Reports Positive Preclinical Data for SARS-CoV-2 Antibodies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
November 23, 2020 7:00 AM ESTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (Nasdaq: TWST) today announced preclinical data for three of its proprietary antibodies against the S1 protein in SARS-CoV-2, the virus that causes COVID-19. The data show that TB202-3 and TB202-63, both single domain VHH nanobodies, protect against weight loss, a key indicator of disease severity, at the lowest dose of 1 mg/kg in a preclinical hamster challenge model. In addition, TB181-36, an IgG antibody discovered through Twists collaboration with Vanderbilt University Medical Center (VUMC), was found to protect... More
